866319-01-9

Upstream product

• 823218-51-5 5-fluoro-3-iodo-pyridin-2-amine 
• 1066-54-2 trimethylsilylacetylene 
• 21717-96-4 2-amino-5-fluoropyridine 
• 869557-43-7 3-bromo-5-fluoropyridin-2-amine 

Downstream Products

• 866318-99-2 5-fluoro-1-tosyl-1H-pyrrolo [2,3-b]pyridine 
• 1417421-99-8 3-bromo-5-fluoro-1-(p-toluenesulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1259279-57-6 5-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(p-toluenesulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1015608-79-3 1-(benzenesulfonyl)-5-fluoropyrrolo[2,3-b]pyridine 
• 866319-00-8 5-fluoro-1H-pyrrolo[2,3‐b]pyridine 
• 936344-74-0 3-ethynyl-5-fluoro-pyridin-2-ylamine 
• 1629869-44-8 pimodivir 
• 1190309-71-7 3-bromo-5-fluoro-1H-pyrrolo-[2,3-b]pyridine 
• 1211524-51-4 2-amino-3-acetyl-5-fluoropyridine 

Relevant academic research and scientific papers

ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE

The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

PYRROLO[2,3-B]PYRIDIN DERIVATIVES AS INHIBITORS OF INFLUENZA VIRUS REPLICATION

Provided herein are compounds of Formula A, B or C that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

FORMULATIONS OF AZAINDOLE COMPOUNDS

The present invention relates to pharmaceutical compositions, each comprising a multitude of granules that make up an intragranular phase of the composition, wherein the granules are produced by fluid bed granulation and comprise a HCI salt of Compound (1

PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas l-lll, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION

A method of preparing a compound of Formula (I) or a pharmaceutically acceptable salt thereof comprises: (a) reacting Compound (1) or (b) a pharmaceutically acceptable salt thereof with Compound (2) in the presence of water, an organic solvent, a base, an

METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION

A method of preparing Compound (1) or a pharmaceutically acceptable salt thereof: comprises: (a) reacting Compound (X): a pharmaceutically acceptable salt thereof with Compound (Y): in the presence of a palladium catalyst and a carbonate or phosphate base

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1)·1/2Η20, Form F of HCl salt of Compound (1)·3Η2

SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS

The invention pertains to heteroaromatic compounds of the formula I, as defined herein, that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.

Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors

Disclosed are compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.